Barrickman 1995.

Methods	Double‐blind, cross‐over study comparing methylphenidate and bupropion
Participants	Number of participants screened: not stated Number of participants included: 18 patients Number of participants followed up: 15 Number of withdrawals: 3 Diagnosis of ADHD: DSM‐III‐R (subtype: not stated) Age: 11.8 (SD 3.3), range 7‐16 IQ: full scale WISC‐R score 106 (SD 10), range 84‐123 Sex: 12 males, 3 females Methylphenidate‐naïve: 5 (33.33%) Ethnicity: white Country: USA Comorbidity: conduct disorder (n = 2), oppositional defiant disorder (n = 2), developmental learning disorder (n = 5) Comedication: none. Before washout methylphenidate (n = 9), methylphenidate + imipramine (n = 1) Sociodemographics: not stated Inclusion criteria: ADHD diagnosis according to DSM‐III‐R Aged 7‐17 years Exclusion criteria: IQ < 70 Any other major Axis I, II or III diagnoses Seizure disorders (bupropion contraindication) or history of seizures, eating disorders (predisposed to bupropion seizures), current use of an MAOI
Interventions	Participants were randomly assigned to 1 of 2 possible drug condition orders, methylphenidate or bupropion. Mean methylphenidate dosage: 31 (n = 11) mg/day (20‐60 mg/day) or 0.7 (n = 0.2) mg/kg/day (0.4‐1.3 mg/kg/day) Administration schedule: morning, noon, and 4 pm if needed Duration of intervention: 6 weeks Washout prior to study initiation: 14 days Medication‐free period between intervention: 14 days Titration period: methylphenidate was administered in a dose of 0.4 mg/kg per day during the first week and the to the maximum effective dose during the next 2 weeks. Dosage was fixed for the final 3 weeks Treatment compliance: not stated
Outcomes	Non‐serious adverse events: Adverse effects checklist monitored by a physician by the end of each week. Physical examination Children's Depression Inventory (CDI), rated each week by physician. Revised Children's Manifest Anxiety Scale (R‐CMAS), rated each week by physician
Notes	Sample calculation: yes Ethics approval: not stated Funding: not stated Vested interest/authors' affiliations: not stated Key conclusions of the study authors: bupropion and methylphenidate were both effective and did not differ in their overall efficacy as treatment for ADHD. Thus, results of nearly all of the rating scales trended in favour of methylphenidate. There is a possibility that this insignificant difference might be a function of the relatively small dose of bupropion used in this study Supplemental information requested through personal email correspondence with the authors in June 2014. No reply